ASCO 2019

REVIEW UroToday

Viewing 1-20 of 156 articles

ASCO 2019: Vofatamab in Combination with Pembrolizumab in WT Metastatic Urothelial Carcinoma: FIERCE-22

ASCO 2019: IMmotion151 Subgroup Analysis: Atezolizumab + Bevacizumab versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology

ASCO 2019: Patient-Reported Outcomes in IMmotion150: Atezolizumab alone or with Bevacizumab versus Sunitinib in First-Line Metastatic Renal Cell Carcinoma

ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features

ASCO 2019: Efficacy of Immune Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid and/or Rhabdoid Metastatic Renal Cell Carcinoma

ASCO 2019: Biomarkers of Outcomes in a Randomized Phase II trial of first-line paclitaxel, ifosfamide, and Cisplatin versus Bleomycin, Etoposide, and Cisplatin for Intermediate- and Poor-Risk Germ Cell Tumors

ASCO 2019: Targeted Therapeutics and Patient Selection in Advanced Urothelial Carcinoma

ASCO 2019: Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy in Men with Clinically Localized, High-Risk Prostate Cancer - CALGB 90203 (Alliance)

ASCO 2019: KEYNOTE-427 Cohort B: First-Line Pembrolizumab Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma

ASCO 2019: First-Line Pembrolizumab Monotherapy in Advanced Clear Cell Renal Cell Carcinoma: Updated Results for KEYNOTE-427 Cohort A

ASCO 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First-line Chemotherapy for Patients with Metastatic Castration-resistant Prostate Cancer: CHEIRON Study

ASCO 2019: Classification and Management of Infrequent Genitourinary Malignancies

ASCO 2019: Balancing Disease Control and Quality of Life in Metastatic Renal Cell Carcinoma

ASCO 2019: Sarcomatoid RCC: Defining a New Treatment Paradigm?

Janssen Seeks to Expand Use of ERLEADA® (apalutamide) in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2019: Clinical Outcomes According to PD-L1 Status and Age in the Prospective International SAUL Study of Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma or Non-UC of the Urinary Tract

ASCO 2019: First-Line Immuno-oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International mRCC Database Consortium

ASCO 2019: Atezolizumab + Bevacizumab Versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology: IMmotion151 Subgroup Analysis - Medical Oncologist Perspective

ASCO 2019: Updated Approaches to Treatment Sequencing in the Era of M0 CRPC Approvals

ASCO 2019: Infigratinib in Upper Tract Urothelial Carcinoma vs Urothelial Carcinoma of the Bladder and Association with Comprehensive Genomic Profiling/Cell-free DNA Results

1
2
3
4
5
6
7
8